$KNSA News

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Screens as Affordable Growth

Kiniksa Pharmaceuticals (KNSA) Shows Explosive Potential with Perfect Minervini Trend Template and 460% EPS Growth

Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally

We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve

Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance

Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results

Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $60

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $59

Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $57

Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earnings Call Highlights: Robust ...

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International Q1 Earnings Call Highlights

Jefferies Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $71

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Surges on Q1 Earnings Beat and Raised ARCALYST Guidance

Kiniksa Pharmaceuticals International, plc 2026 Q1 - Results - Earnings Call Presentation

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals International shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY2026 sales guidance above estimates.

Kiniksa Pharmaceuticals International shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY2026 sales guidance above estimates.

Kiniksa Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript